公开(公告)号：EP1747206A1

公开(公告)日：2007-01-31

申请号：EP05744712.0

申请日：2005-04-28

Applicant: ABBOTT LABORATORIES

Inventor： CARROLL, William, A. ,  PEREZ-MEDRANO, Arturo ,  FLORJANCIC, Alan, S. ,  NELSON, Derek, W. ,  PEDDI, Sridhar ,  BUNNELLE, Eric, M. ,  HIRST, Gavin, C. ,  LI, Biqin ,  LI, Tongmei

IPC: C07D257/06 ,  C07D403/12 ,  C07D401/12 ,  A61K31/41

CPC classification number: C07D487/04 ,  C07D257/06 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/12 ,  C07D405/12 ,  C07D409/12 ,  C07D409/14 ,  C07D413/12 ,  C07D417/12 ,  C07D417/14 ,  C07D487/08 ,  C07D491/04 ,  C07D491/048 ,  C07D491/08

Abstract: A compound having Formula (I) or Formula (II) is disclosed as an P2X7 antagonist, wherein A, B, C, Y, Y, Z, m, v, R1, R2, R3, R4, and R5, are as defined in the description. Methods and compositions for treating disease or condition modulated by P2X7 are also disclosed.

Abstract translation: 具有式（I）或式（II）的化合物被公开为P2X 7拮抗剂，其中A，B，C，Y，Y，Z，m，v，R 1，R 2，R 3，R 4和R 5如上定义 在描述中。 还公开了用于治疗由P2X7调节的疾病或病症的方法和组合物。

公开(公告)号：EP2346843A2

公开(公告)日：2011-07-27

申请号：EP09792301.5

申请日：2009-09-08

Applicant: Abbott Laboratories

Inventor： CARROLL, William, A. ,  DART, Michael, J. ,  FROST, Jennifer, M. ,  KOLASA, Teodozyj ,  LI, Tongmei ,  LIU, Bo ,  PEREZ-MEDRANO, Arturo ,  PATEL, Meena ,  WANG, Xueqing ,  PEDDI, Sridhar

IPC: C07D277/46 ,  C07D417/06 ,  C07D417/14 ,  A61K31/427 ,  A61P29/00

CPC classification number: C07D417/06 ,  C07D277/46 ,  C07D417/14

Abstract: The present application relates to cannabinoid receptor ligands of formula (I), wherein X
1 , A
1 , R
x , R
2 , R
3 , R
4 , and z are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods for treating conditions and disorders using such compounds and compositions.

公开(公告)号：EP2274306A1

公开(公告)日：2011-01-19

申请号：EP09719609.1

申请日：2009-03-11

Applicant: Abbott Laboratories

Inventor： KOLASA, Teodozyi ,  FROST, Jennifer, M. ,  PATEL, Meena, V. ,  LATSHAW, Steven, P. ,  PEREZ-MEDRANO, Arturo ,  WANG, Xueqing ,  TIETJE, Karin, Rose, Marie ,  PEDDI, Sridhar ,  CARROLL, William, A.

IPC: C07D417/06 ,  A61K31/426

CPC classification number: C07D417/06

Abstract: Disclosed herein are compounds of formula (I) wherein R
1 , R
2 , R
3 , R
25a , R
26a , X, and n are as defined in the specification. Pharmaceutical compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and pharmaceutical compositions are also described.

公开(公告)号：EP2222165A1

公开(公告)日：2010-09-01

申请号：EP08852528.2

申请日：2008-11-20

Applicant: ABBOTT LABORATORIES

Inventor： FLORJANCIC, Alan, S. ,  DART, Michael, J. ,  RYTHER, Keith, B. ,  PEREZ-MEDRANO, Arturo ,  CARROLL, William, A. ,  PATEL, Meena, V. ,  TIETJE, Karin, Rosemarie ,  LI, Tongmei ,  KOLASA, Teodozyj ,  GALLAGHER, Megan, E. ,  PEDDI, Sridhar ,  FROST,Jennifer, M. ,  NELSON, Derek, W.

IPC: A01N43/42

CPC classification number: C07D417/12 ,  C07D277/46 ,  C07D417/06 ,  C07D513/04 ,  C07D513/20

Abstract: The present invention relates to compounds of formula (I), or pharmaceutical salts, prodrugs, salts of prodrugs, or combinations thereof, formula (I). wherein R1, R2, R3, R4, and L1 are defined in the specfication, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions. The present invention also relates to compounds of formula (II), or pharmaceutical salts, prodrugs, salts of prodrugs, or combinations thereof, formula (II). wherein R1a, R2a, Rx, and n are as defined in the specification, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.

公开(公告)号：EP2219629A1

公开(公告)日：2010-08-25

申请号：EP08837396.4

申请日：2008-10-08

Applicant: Abbott Laboratories

Inventor： CARROLL, William A. ,  PEDDI, Sridhar ,  PEREZ-MEDRANO, Arturo ,  DART, Michael J. ,  NELSON, Derek W. ,  LI, Tongmei ,  LIU, Bo ,  KOLASA, Teodozyj ,  FROST, Jennifer ,  WANG, Xueqing ,  LATSHAW, Steven, P.

IPC: A61K31/015 ,  A61P43/00

CPC classification number: C07D405/06 ,  C07D405/14 ,  C07D413/06 ,  C07D413/14 ,  C07D417/06 ,  C07D417/14

Abstract: The present invention relates compounds of formula (I), as defined in the specification, pharmaceutical compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and pharmaceutical compositions.

Abstract translation: 本发明涉及如说明书中所定义的式（I）化合物，包含此类化合物的药物组合物，以及使用此类化合物和药物组合物治疗病症和障碍的方法。

公开(公告)号：EP2038266A2

公开(公告)日：2009-03-25

申请号：EP07797862.5

申请日：2007-05-30

Applicant: ABBOTT LABORATORIES

Inventor： DART, Michael J. ,  CARROLL, William A. ,  FLORJANCIC, Alan S. ,  FROST, Jennifer M. ,  GALLAGHER, Megan E. ,  LI, Tongmei ,  NELSON, Derek W. ,  PATEL, Meena V. ,  PEDDI, Sridhar ,  PEREZ-MEDRANO, Arturo ,  RYTHER, Keith B. ,  TIETJE, Karin Rosemarie ,  KOLASA, Teodozyj

IPC: C07D277/46 ,  C07D277/48 ,  C07D277/60 ,  C07D417/06 ,  C07D417/12 ,  C07D417/14 ,  C07D513/04 ,  A61K31/426 ,  A61K31/427 ,  A61K31/428 ,  A61K31/429 ,  A61P29/00

CPC classification number: C07D277/82 ,  C07D277/46 ,  C07D277/48 ,  C07D277/60 ,  C07D417/06 ,  C07D417/12 ,  C07D477/14 ,  C07D513/04

Abstract: The present invention relates to compounds of formula (I), or pharmaceutical salts, prodrugs, salts of prodrugs, or combinations thereof, wherein R1, R2, R3, R4, and L1 are defined in the specfication, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions. The present invention also relates to compounds of formula (II), or pharmaceutical salts, prodrugs, salts of prodrugs, or combinations thereof, wherein R1a, R2a and (Rx)n are as defined in the specification, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.

公开(公告)号：EP1951689A1

公开(公告)日：2008-08-06

申请号：EP06836800.0

申请日：2006-11-02

Applicant: ABBOTT LABORATORIES

Inventor： CARROLL, William, A. ,  FLORJANCIC, Alan, S. ,  PEREZ-MEDRANO, Arturo ,  PEDDI, Sridhar

IPC: C07D249/06 ,  C07D249/08 ,  C07D401/14 ,  C07D405/06 ,  C07D405/04 ,  C07D401/06 ,  C07D401/04 ,  C07D409/06 ,  C07D401/12 ,  C07D409/14 ,  C07D409/12 ,  A61K31/4192 ,  A61K31/4196 ,  A61P25/00

CPC classification number: C07D249/06 ,  C07D249/08 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D405/04 ,  C07D405/06 ,  C07D409/06 ,  C07D409/12 ,  C07D409/14

Abstract: The invention is directed to compounds that are P2X7 antagonist and have the formula (I) or (II) or a pharmaceutically acceptable salt, prodrug, salt of a prodrug or a combination thereof, wherein R1, R2, and R3 are defined in the specification. The invention is also directed to a method of selectively inhibiting P2X7 activity comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound of formula (III), (IV) or (V) wherein R6, R7, R8, R9, R10, and R11 are defined in the specification.